INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform...

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease...

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech ...

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update...

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration...

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thurs...

INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes...

INmune Bio Inc. Announces 2025 Results and Provides Business Update...

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, Ma...

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach...

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar...

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB...

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Ear...

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB...

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Init...